Peritoneal fibrosis intervention

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Kaneko, Kayo ^a   Hamada, Chieko ^a   Tomino, Yasuhiko ^a,b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Intervention; Peritoneal fibrosis; Tranilast

Indexed keywords

ADENOVIRUS VECTOR; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DECORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EMODIN; ENALAPRIL; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; LISINOPRIL; LOSARTAN; PENTOXIFYLLINE; PYRIDOXAMINE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; VALSARTAN; VASCULOTROPIN ANTIBODY;

BIOCOMPATIBILITY; BONE MARROW CELL; CELL LOSS; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONFERENCE PAPER; DIALYSATE; DRUG TARGETING; FIBROSIS; HUMAN; INFLAMMATION; LONG TERM CARE; MEMBRANE TRANSPORT; MESOTHELIUM CELL; NONHUMAN; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PERITONITIS; PRIORITY JOURNAL; QUALITY OF LIFE; SOLUTE; ULTRAFILTRATION; UREMIA; VASCULAR DISEASE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOCOMPATIBLE MATERIALS; DIALYSIS SOLUTIONS; EPITHELIAL CELLS; FIBROSIS; HUMANS; HYALURONIC ACID; INFLAMMATION MEDIATORS; PEPTIDE FRAGMENTS; PERITONEAL DIALYSIS; PERITONEUM; PROCOLLAGEN; RISK FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 35748931790     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
2. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Rohrborn A, et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int 2001; 59(Suppl 78): S42-7.
3. Devuyst O, Topley N, Williams JD. Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrol Dial Transplant 2002; 17(Suppl 3):12-15.
4. Naiki Y, Maeda Y, Matsuo K, Yonekawa S, Sakaguchi M, Iwamoto I, et al. Involvement of TGF-β signal for peritoneal sclerosing in continuous ambulatory peritoneal dialysis. J Nephrol 2003; 16:95-102.
5. Kang DH, Hong YS, Lim HJ, Choi JH, Han DS, Yoon KI. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-β1 of human peritoneal mesothelial cells: effect of cytokine costimulation. Perit Dial Int 1999; 19:221-30.
6. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-β1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12:2029-39.
7. Moussad EE, Brigstock DR. Connective tissue growth factor: what's in a name? Mol Genet Metab 2000; 71:276-92.
8. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GR, et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12:2434-41.
9. Kim YS, Kim BC, Song CY, Hong HK, Moon KC, Lee HS. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-β. J Lab Clin Med 2001; 138:59-68.
10. Honda K, Nitta K, Horita S, Yamura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
11. Combet S, Ferrier ML, Van Landschoot M, Stoenoiu M, Moulin P, Miyata T, et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001; 12:2146-57.
12. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283:F209-20.
13. Rougier JP, Guia S, Hagege J, Nguyen G, Ronco PM. PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-β1. Kidney Int 1998; 54:87-98.
14. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Peril Dial Int 2005; 25:38-47.
15. Kiribayashi K, Masaki T, Naito T, Ogawa T, Ito T, Yorioka N, et al. Angiotensin II induces fibronectin expression in human peritoneal mesothetial cells via ERK1/2 and p38 MAPK. Kidney Int 2005; 67:1126-35.
16. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
17. Bajo MA, Selgas R, Castro MA, del Peso G, Diaz C, Sanchez-Tomero JA, et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Peril Dial Int 2000; 20:742-7.
18. le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005; 25(Suppl 3):S64-8.
19. Yung S, Liu ZH, Lai KN, Li LS, Chan TM. Emodin ameliorates glucose-induced morphologic abnormalities and synthesis of transforming growth factor β1 and fibronectin by human peritoneal mesothelial cells. Perit Dial Int 2001; 21(Suppl 3):S41-7.
20. Chan TM, Leung JK, Tsang RC, Liu ZH, Li LS, Yung S. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int 2003; 64: 519-33.
21. Hung KY, Huang JW, Chen CT, Lee PH, Tsai TJ. Pentoxifylline modulates intracellular signalling of TGF-β in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2003; 18:670-6.
22. Fang CC, Yen CJ Chen YM, Chu TS, Lin MT, Yang JY, et al. Diltiazem suppresses collagen synthesis and IL-1β-induced TGF-β1 production on human peritoneal mesothelial cells. Nephrol Dial Transplant 2006; 21:1340-7.
23. Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits TGF-β-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int 2001; 60:1249-57.
24. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 2002; 13:721-8.
25. Fukuyama J, Ichikawa K, Miyazawa K, Hamano S, Shibata N, Ujiie A. Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Jpn J Pharmacol 1996; 70:321-7.
26. Fukuyama J, Ichikawa K, Hamano S, Shibata N. Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet. Eur J Pharmacol 1996; 318:327-32.
27. Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N. TGF-β1 induced by high glucose is controlled by angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on cultured human peritoneal mesothelial cells. Perit Dial Int 2005; 25:483-91.
28. Duman S, Gunal AI, Sen S, Asci G, Ozkahya M, Terzioglu E, et al. Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution? Perit Dial Int 2001; 21:219-24.
29. Duman S, Sen S, Duman C, Oreopoulos DG. Effect of valsartan versus lisinopril on peritoneal sclerosis in rats. Int J Artif Organs 2005; 28:156-63.
30. Girl SN, Biring I, Nguyen T, Wang O, Hyde DM. Abrogation of bleomycin-induced lung fibrosis by nitric oxide synthase inhibitor, aminoguanidine in mice. Nitric Oxide 2002; 7:109-18.
31. Zareie M, Tangelder GJ, ter Wee PM, Hekking LH, van Lambalgen AA, Keuning ED, et al. Beneficial effects of aminoguanidine on peritoneal microdrculation and tissue remodelling in a rat model of PD. Nephrol Dial Transplant 2005; 20:2783-92.
32. Kakuta T, Tanaka R, Satoh Y, Izuhara Y, Inagi R, Nangaku M, et al. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int 2005; 68:1326-36.
33. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
34. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 2004; 66:1677-85.
35. Di Paolo N, Sacchi G, Vanni L, Corazzi S, Terrana B, Rossi P, et al. Autologous peritoneal mesothelial cell implant in rabbits and peritoneal dialysis patients. Nephron 1991; 57:323-31.
36. Hekking LH, Harvey VS, Havenith CE, van den Born J, Beelen RH, Jackman RW, et al. Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis. Perit Dial Int 2003; 23:323-30.
37. Nagy JA, Shockley TR, Masse EM, Harvey VS, Hoff CM, Jackman RW. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface. Gene Ther 1995; 2:402-10.
38. Hekking LH, Zweers MM, Keuning ED, Driesprong BA, de Waart DR, Beelen RH, et al. Apparent successful mesothelial cell transplantation hampered by peritoneal activation. Kidney Int 2005; 68:2362-7.